Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 12—December 2008
CME ACTIVITY - Research

Clinical Characteristics and Molecular Subtyping of Vibrio vulnificus Illnesses, Israel

Ronit Zaidenstein, Chantal Sadik, Larisa Lerner, Lea Valinsky, June Kopelowitz, Ruth Yishai, Vered Agmon, Michele B. Parsons, Cheryl Bopp, and Miriam WeinbergerComments to Author 
Author affiliations: Assaf Harofeh Medical Center, Zerifin, Israel (R. Zaidenstein, M. Weinberger); Israel Ministry of Health, Jerusalem, Israel (C. Sadik, L. Lerner, L. Valinsky, J. Kopelowitz, R. Yishai, V. Agmon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Parsons, C. Bopp); Tel Aviv University, Ramat Aviv, Israel (M. Weinberger)

Main Article

Figure 1

Figure 1 - PCR restriction fragment length polymorphism of Vibrio vulnificus cytotoxin gene vvhA. A) PCR amplicon of vvhA gene restriction digested with B) PstI or C) KpnI. Gel shows molecular size standards (M) and V. vulnificus biotype 3 (lanes 1–3) and biotype 1 (lane 4).

Figure 1. PCR restriction fragment length polymorphism of Vibrio vulnificus cytotoxin gene vvhA. A) PCR amplicon of vvhA gene restriction digested with B) PstI or C) KpnI. Gel shows molecular size standards (M) and V. vulnificus biotype 3 (lanes 1–3) and biotype 1 (lane 4).

Main Article

Page created: July 22, 2010
Page updated: July 22, 2010
Page reviewed: July 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external